<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In this issue of Blood, Dutt and colleagues address the selective effect of ribosomal protein haploinsufficiency on erythroid development observed in congenital Diamond-Blackfan <z:hpo ids='HP_0001903'>anemia</z:hpo> (<z:chebi fb="28" ids="35299">DBA</z:chebi>) and acquired <z:e sem="disease" ids="C0740302" disease_type="Disease or Syndrome" abbrv="">5q-syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Their findings reveal a selective induction of p53 in the erythroid lineage in response to reduced expression of ribosomal proteins affected in these diseases </plain></SENT>
<SENT sid="2" pm="."><plain>Moreover, the selective effect on erythropoiesis can be mimicked by activating p53 with the compound <z:chebi fb="0" ids="46742">nutlin-3</z:chebi> and prevented by pifithrin-, an inhibitor of p53 activation </plain></SENT>
</text></document>